DataMeds AI, Inc. (MEDS) AI Stock Summary

Snapshot

DataMEDS AI is a tiny, cash-strapped micro-cap health IT and pharmacy company. Revenue grew 28.7% to $23.3M in FY 2025, but gross margin turned negative (-41.3%), meaning each sale loses money before other costs. The company burned $10.9M in free cash flow and ended the year with only $43K in cash against $24.8M in debt. Share count rose 36.7% YoY, and it completed two reverse splits in the past year.

What's Happening Right Now

• Tue 8th Sep '26 · Partnership: On Sep 8, 2026, DataMEDS and Tollo Health partnered with the NFL Alumni Association to roll out a telehealth and pharmacy-access campaign for rural communities through the Health Lives Here app.
• Mon 17th Aug '26 · Earnings: On Aug 17, 2026, DataMEDS reported Q2 2026 revenue of $1.779M (up 14% sequentially), disclosed a $6.5M funding round, a completed 1-for-50 reverse split to address delisting risk, and a meme coin token distribution to shareholders.
• Wed 12th Aug '26 · Pharmacy update: On Aug 12, 2026, DataMEDS said its Corexa Pharmacy division stabilized at over $600,000 in July 2026 revenue and completed integration of its online store, adding GLP-1 drug offerings.
• Wed 29th Jul '26 · Licensing deal: On Jul 29, 2026, DataMEDS expanded its blockchain data-licensing agreement with Datavault AI, extending its PharmacyChain technology beyond pharmaceutical distribution into broader healthcare and wellness data monetization.
• Fri 26th Jun '26 · Rebrand: On Jun 26, 2026, the company was renamed DataMeds AI, Inc. from Wellgistics Health, reflecting a pivot toward a vertically integrated data, pharmacy, and telemedicine model.

Ownership

Institutions hold 1.4%, insiders hold 0.5%.

Bottom Line

DataMEDS AI is a distressed micro-cap: it holds just $43K in cash against $24.8M in debt and burned nearly $11M in free cash flow last year, a combination that points to an immediate cash crunch. Two reverse splits in the last twelve months and 36.7% share dilution are signs the stock has been under sustained pressure for a long time. Revenue growth and a steady stream of partnership announcements are the only bright spots, but the balance sheet is the dominant story here.